II 

116TH CONGRESS 

2D SESSION S. 3942 

To establish the position of Chief Pharmaceutical and Medical Supply Chain 

Negotiator in the Office of the United States Trade Representative, 

to be responsible for conducting trade negotiations and enforcing trade 

agreements related to acts, policies, and practices of foreign governments 

that fail to appropriately reward United States innovation with respect 

to pharmaceuticals, to advance domestic production of life-saving medicines, and to secure the United States medical supply chain to eliminate 

reliance on foreign governments, and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

JUNE 11, 2020 

Mrs. LOEFFLER introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To establish the position of Chief Pharmaceutical and Medical Supply Chain Negotiator in the Office of the United 

States Trade Representative, to be responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign 

governments that fail to appropriately reward United 

States innovation with respect to pharmaceuticals, to 

advance domestic production of life-saving medicines, and 

to secure the United States medical supply chain to 

eliminate reliance on foreign governments, and for other 

purposes. 


pbinns on DSKJLVW7X2PROD with BILLS
2 

•S 3942 IS

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Securing America’s 

5 Medical Supply Chain and Advancing the Production of 

6 Life Saving Medicines Act’’. 

7 SEC. 2. CHIEF PHARMACEUTICAL AND MEDICAL SUPPLY 

8 CHAIN NEGOTIATOR. 

9 (a) IN GENERAL.—Section 141 of the Trade Act of 

10 1974 (19 U.S.C. 2171) is amended— 

11 (1) in subsection (b)(2)— 

12 (A) by striking ‘‘and one Chief Innovation 

13 and Intellectual Property Negotiator’’ and in14 serting ‘‘one Chief Innovation and Intellectual 

15 Property Negotiator, and one Chief Pharma16 ceutical and Medical Supply Chain Negotiator’’; 

17 (B) by striking ‘‘or the Chief Innovation 

18 and Intellectual Property Negotiator’’ and in19 serting ‘‘the Chief Innovation and Intellectual 

20 Property Negotiator, or the Chief Pharma21 ceutical and Medical Supply Chain Negotiator’’; 

22 and 

23 (C) by striking ‘‘and the Chief Innovation 

24 and Intellectual Property Negotiator’’ and in25 serting ‘‘the Chief Innovation and Intellectual 


pbinns on DSKJLVW7X2PROD with BILLS
3 

•S 3942 IS

1 Property Negotiator, and the Chief Pharma2 ceutical and Medical Supply Chain Negotiator’’; 

3 and 

4 (2) in subsection (c), by adding at the end the 

5 following new paragraph: 

6 ‘‘(7) The principal function of the Chief Pharma7 ceutical and Medical Supply Chain Negotiator shall be to 

8 conduct trade negotiations and to enforce trade agree9 ments relating to United States pharmaceutical products 

10 and services and medical supply chains. The Chief Phar11 maceutical and Medical Supply Chain Negotiator shall be 

12 a vigorous advocate on behalf of United States pharma13 ceutical and medical supply chain interests. The Chief 

14 Pharmaceutical and Medical Supply Chain Negotiator 

15 shall perform such other functions as the United States 

16 Trade Representative may direct.’’. 

17 (b) COMPENSATION.—Section 5314 of title 5, United 

18 States Code is amended by striking ‘‘Chief Innovation and 

19 Intellectual Property Negotiator, Office of the United 

20 States Trade Representative.’’ and inserting the following: 

21 ‘‘Chief Innovation and Intellectual Property Nego22 tiator, Office of the United States Trade Representative. 

23 ‘‘Chief Pharmaceutical and Medical Supply Chain 

24 Negotiator, Office of the United States Trade Representa25 tive.’’. 


pbinns on DSKJLVW7X2PROD with BILLS
4 

•S 3942 IS

1 (c) REPORT REQUIRED.—Not later than one year 

2 after the appointment of the first Chief Pharmaceutical 

3 and Medical Supply Chain Negotiator pursuant to para4 graph (2) of section 141(b) of the Trade Act of 1974, as 

5 amended by subsection (a), and annually thereafter, the 

6 United States Trade Representative shall submit to the 

7 Committee on Finance of the Senate and the Committee 

8 on Ways and Means of the House of Representatives a 

9 report describing in detail— 

10 (1) enforcement actions taken by the Trade 

11 Representative during the one-year period preceding 

12 the submission of the report to ensure the protection 

13 of United States pharmaceutical products and serv14 ices and medical supply chains; and 

15 (2) other actions taken by the Trade Represent16 ative to advance United States pharmaceutical prod17 ucts and services and medical supply chain interests. 

Æ 


pbinns on DSKJLVW7X2PROD with BILLS